Periductal myxoid stroma identifies ductal carcinoma in situ at risk of invasive recurrence

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Abstract Overtreatment of breast ductal carcinoma in situ (DCIS) remains a major clinical problem because clinicopathologic criteria are insufficient to define the invasive potential. We evaluated whether periductal stromal morphology in diagnostic hematoxylin-eosin sections predicts invasive recurrence among 711 DCIS patients from the randomized SweDCIS trial, who underwent breast-conserving surgery with or without radiotherapy. Two raters scored the proportion of DCIS ducts surrounded by myxoid stroma. Eighty patients developed ipsilateral invasive recurrence as first event post surgery. Cause-specific Cox regression revealed that an increase in myxoid stroma was associated with a higher risk of invasive recurrence (adjusted HR per 10% increase = 1.16 [1.04-1.28]; p = 0.005). The 20-year cumulative incidence of invasive recurrence was more than doubled for lesions with at least 10% myxoid stroma compared with those with less than 10% myxoid stroma (15.7% vs 7.1%). Periductal myxoid stroma may be a simple histologic marker for the invasive potential of DCIS.